ADIAOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

Adia Med, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.13−0.01 (-7.14%)

Close on Oct 19, 2026

Market cap: $20.98M
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Adia Med has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Adia Med filed with the SEC

Oct 5, 2026, 4:49 PM ET
VERIFICATION Under penalties of perjury, I declare that I have read the foregoing and that the facts alleged are true to the best of my knowledge and belief. - 5 -
Other events · EX-99.1 to Form 8-K

Where these numbers come from

Parsed from the XBRL in Adia Med's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ADIA.

Revenue growth10879.7% · median -5.1%

Gross margin27.4% · median 69.8%

Operating margin-52.3% · median -1049.0%

Net margin-56.5% · median -946.2%

Company	Revenue	Growth
LGVN	$1.19M	-42.7%
RAJAF	$882.53K	–
PROK	$818.00K	+55.2%
ADIA	$700.51K	+10879.7%
AAGH	$363.33K	-5.1%
AKAN	–	–

Company

Exchange: OTC
Industry: Medicinal Chemicals & Botanical Products
Fiscal year ends: December 31
Employees: 3
Held by institutions: 0.0%
Auditor: Astra Audit & Advisory
SEC CIK: 1160420

Advertisement
300 × 250